Overview

An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

Status:
Completed

Trial end date:
2019-03-10

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization to the liver in subjects with and without moderate to severe nonalcoholic steatohepatitis (NASH) by planar and SPECT/CT imaging. This study is designed to evaluate the safety and tolerability of Tc99m-tilmanocept in subjects with NASH.

Phase:

Phase 1

Details

Lead Sponsor:

Navidea Biopharmaceuticals

Treatments:

Technetium Tc 99m Sulfur Colloid